热门资讯> 正文
BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment
2024-09-04 00:40
12:40 PM EDT, 09/03/2024 (MT Newswires) -- BioVie (BIVI) said Tuesday the US Food and Drug Administration has authorized its investigational new drug application to evaluate bezisterim for treating neurological symptoms associated with long COVID.
The approval allows BioVie to proceed with a phase 2 trial and positions the company to receive an additional $12.6 million in grant funding from the US Department of Defense, the company said.
The trial will assess the safety and efficacy of bezisterim, an anti-inflammatory treatment, in addressing long COVID's neurocognitive symptoms, BioVie said.
BioVie shares were down 5% in recent trading.
Price: 2.64, Change: -0.14, Percent Change: -5.04
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
